Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction

Advances in Therapy

Volumn 23, Issue 6, 2006, Pages 1052-1059

  Yalta, Kenan ^a   Yilmaz, Ahmet ^a   Turgut, Okan Onur ^a   Erselcan, Taner ^a   Yilmaz, Mehmet Birhan ^a   Karadas, Filiz ^a   Yontar, Can ^a   Tandogan, Izzet ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Carcinoembryonic antigen; Left ventricular systolic dysfunction; Myocardial infarction; Serum carbohydrate antigen

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATINE KINASE MB; TROPONIN I; TROPONIN T; TUMOR MARKER;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; ST SEGMENT ELEVATION; TRANSTHORACIC ECHOCARDIOGRAPHY;

CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATINE KINASE, MB FORM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE VOLUME; TROPONIN I;

EID: 33847396215     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850225     Document Type: Article

References (30)

1. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.
2. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer. 1984;50:765-769.
3. Lazzarino M, Orlandi E, Klersy C, et al. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer. 1998;82:576-582.
4. Sakamoto K, Haga Y, Yoshimura R, Egami H, Yokoyama Y, Akagi M. Comparative effectiveness of the tumour diagnostics CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut. 1987;28:323-329.
5. Klapdor R, Klapdor U, Bahlo M, et al. CA 125 in carcinomas of the digestive tract. Dtsch Med Wochenschr. 1984;199:1949-1954.
6. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer. 1987;59:213-217.
7. Seo T, Ikeda Y, Onaka H, et al. Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J. 1993;57:489-494.
8. Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA125 and its relation to cardiac function. Am Heart J. 1999;137:1044-1049.
9. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities and short term prognosis. J Am Coll Cardiol. 2003;41:1805-1811.
10. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1996;104:66-73.
11. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1996;14:2843-2877.
12. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of left ventricle by two-dimensional echocardiography. American Society of Echocardiography on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
13. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215-245.
14. Ozguroglu M, Turna H, Demir G, et al. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma. Am J Clin Oncol. 1999;22:615-618.
15. Lazzarino M, Orlandi E, Klersy C, et al. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer. 1998;82:576-582.
16. Zacharos ID, Efstathiou SD, Petreli E, et al. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma. Eur J Haematol. 2002;69:221-226.
17. Gallup DG, Talledo E. Management of the adnexal mass in the 1990s. South Med J. 1997;90:972-981.
18. Halila H, Stenman UH, Seppala M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer. 1986;57:1327-1329.
19. Barbieri RL, Niloff JM, Bast RC, Schaetzi RN, Kirstner RW, Knapp RC. Elevated serum concentrations of CA 125 in patients with advanced endometriosis. Fertil Steril. 1986;45:630-634.
20. Candocia SA, Locker GY. Elevated serum CA 125 secondary to tuberculous peritonitis. Cancer. 1993;72:2016-2018.
21. Okazaki K, Mizuno K, Katoh K, Hashomoto S, Fukuchi S. Tuberculous peritonitis with extraordinarily high serum CA 125. J Med. 1992;23:353-361.
22. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215-245.
23. Gallup DG, Talledo E. Management of the adnexal mass in the 1990s. South Med J. 1997;90:972-981.
24. Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol. 1988;72:23-27.
25. Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA 125 levels in patients with chronic congestive heart failure: correlation with clinical and echocardiographic parameters. Eur J Heart Fail. 2005;7:199-203.
26. Camera A, Villa MR, Rocco S, et al. Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement. Cancer. 2000;88:75-78.
27. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol. 1997;79:1128-1131.
28. Kubonishi I, Bandobashi K, Murata N, et al. High serum levels of CA125 and interleukin-6 in a patient with Ki-1 lymphoma. Br J Haematol. 1997;98:450-452.
29. Maytin M, Colucci WS. Molecular and cellular mechanisms of myocardial remodeling. J Nucl Cardiol. 2002;9:319-327.
30. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 1995;96:1093-1099.